It was clear that the abject failure of aducanumab was not going to deter Biogen from pursuing the development of Alzheimer’s disease projects, and today the group shed a little more light on its strategy here. On its first-quarter analyst call Biogen justified having pressed on with aducanumab despite the failure of every other preceding beta-amyloid project, arguing that “we followed the science”, and highlighted five Alzheimer’s assets that were very much still in development. As far as strategic changes go, the group said it would no longer run large Alzheimer’s trials with subjective endpoints, instead seeking out a more targeted approach. While the growing focus is now on targeting tau, another anti-beta-amyloid MAb, BAN2401, remains in development, and bizarrely entered a registrational study the day after aducanumab flunked its two phase III trials (Eisai and Biogen throw good money after bad, March 22, 2019). Today Biogen left open the possibility that the decision to advance BAN2401 had been taken not by it but by its partner Eisai, pointedly refusing to answer analysts' questions about just how much control it retained over its joint Alzheimer’s projects.
|Biogen's remaining Alzheimer's portfolio|
|Elenbecestat||BACE inhibitor||Phase III||Partnered with Eisai|
|BAN2401||Anti-beta-amyloid MAb||Moving into phase III||Partnered with Eisai|
|Gosuranemab/BIIB092||Anti-tau MAb||Phase II|
|BIIB076||Anti-tau MAb||Phase I||Partnered with Eisai|
|IONIS-MAPTRx||Tau antisense oligonucleotide||Phase I||Partnered with Ionis|
|Source: Q1 2019 presentation.|